Invivyd develops monoclonal antibody candidates for the prevention or treatment of serious viral diseases, starting with COVID-19. The company utilizes a proprietary integrated technology platform to create potent antibodies that resist virus evolution better than the human immune system. Their pipeline focuses on generating these vaccine-alternative antibodies for high-need indications including influenza.
Funding
$336M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals, especially those who are vulnerable, face significant risks from serious viral infectious diseases, including COVID-19 and influenza. Traditional approaches to combating these threats can be slow to adapt to new viral strains, leaving gaps in protection.
Solution
Invivyd is developing a platform to create and optimize monoclonal antibodies that protect vulnerable populations from serious viral threats. The Invymab platform leverages viral surveillance, predictive modeling, and antibody engineering to discover and refine antibody candidates. This approach aims to provide continuous protection against evolving viral strains, starting with COVID-19 and expanding to influenza and other high-need indications.
Target Audience
The primary target audience includes vulnerable individuals at high risk of serious complications from viral infections, as well as healthcare providers seeking effective preventative and therapeutic options.
Features
- Viral surveillance to monitor emerging viral variants and identify potential threats.
- Predictive modeling to forecast viral evolution and guide antibody design.
- Advanced antibody engineering techniques to optimize antibody candidates for efficacy and safety.
- Pipeline of monoclonal antibody candidates for prevention and treatment of serious viral diseases.